Who uses Alamar NULISA?
NULISA panels detect very low levels of proteins in blood, such as brain and inflammation markers, by pairing antibodies with DNA barcodes. It's made by Alamar Biosciences. 79 bioRxiv and medRxiv preprints since April 2025 say they used NULISA, 43 in the last 6 months. Updated daily (as of Nov 16)
Is NULISA use still growing?
New: in preprints since Q2 2025, with 43 in the last 6 months, up from 18 in the six months before.
The last bar is the quarter so far. The % over each year compares it with the year before, as a share of all preprints.
How does NULISA compare with other affinity proteomics platforms?
NULISA is second, with 25% of their uses in Jun–Nov 2026, up from 12% the year before. Olink leads with 54%.
Which institutions use NULISA most?
The institutions using NULISA most are University of Pittsburgh, Emory University and Stanford University.
Institutions
University of Pittsburgh7
Emory University6
Stanford University4
Washington University in St. Louis3
University of Oxford3
Where the labs are
The lab's institution and country are the corresponding author's.
Latest preprints using NULISA
Who started using NULISA recently?
22 institutions posted their first preprint using NULISA since April 2025 in the last 6 months, including The Jackson Laboratory, University of Wisconsin–Madison and Amsterdam UMC.
The Jackson LaboratoryJul 6, 2026
University of Wisconsin–MadisonAug 31, 2026
Amsterdam UMCJun 16, 2026
- Noselab GmbHJun 17, 2026
Feinstein Institutes for Medical ResearchJun 22, 2026
University of BresciaJun 24, 2026
University of New South WalesJul 7, 2026
- NYU Grossman School of MedicineJul 8, 2026
Friedrich-Alexander University Erlangen-NürnbergJul 10, 2026
Columbia UniversityJul 31, 2026
An institution counts as new when its first preprint using NULISA since April 2025 was posted in the last 6 months; the date is that first preprint.
What do labs use alongside NULISA?
Preprints using NULISA most often also use NextSeq, Chromium and NovaSeq X. The count is preprints using both.
What is NULISA used for?
Preprints using NULISA are most often in neurology, neuroscience and immunology.
Fields
Neurology 42Neuroscience 9Immunology 7Epidemiology 3Psychiatry and clinical psychology 3Systems biology 2
Where the work was published
- Human Genetics and Genomics Advances1
- Neurological Research and Practice1
- Free Radical Biology and Medicine1
- Nature Immunology1
- Journal of Clinical Investigation1
- European Heart Journal1
How we count which preprints use each platform
An AI model reads each preprint in full — its text, its tables and its supplementary files — and lists the products the authors used. A preprint counts for a platform when that record says the lab used it in this work, not when it only analyzed data others made with it or only mentioned it. Each preprint counts once, by its first version, if it was first posted on bioRxiv or medRxiv in April 2025 or later. We read new preprints within days of posting, so the newest ones (through Nov 16, 2026) are already counted, but those days are not complete yet. Six-month counts and growth figures stop at Nov 12, 2026, the last day nearly every preprint has been read, and charts draw a quarter that is still being counted in a paler color. A preprint that used two platforms counts for both. Each title links to the preprint on bioRxiv or medRxiv; we show no preprint text and no author names. Updated daily, most recently on Nov 16, 2026.